SERPINE1 and glomerulosclerosis: These data demonstrate that inhibition of aldosterone can decrease PAI-1 in vivo, and suggest that targeting of both angiotensin and aldosterone may be necessary for optimal effect on PAI-1 and progression of glomerulosclerosis.